SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as its community eagerly anticipates the start of a new yearly cycle, with many predicting a significant bullish reversal based on historical performance. Investors are discussing aggressive accumulation, forecasting substantial long-term growth and positioning LTC as a strong contender for major appreciation in upcoming crypto market upturns.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is trending due to significant community speculation around its extremely low share float, fueling expectations for a short squeeze and a potential multi-day parabolic run. Traders are actively observing rapidly increasing volume and strong accumulation, with many drawing comparisons to other micro-cap stocks known for explosive gains. Despite recent corporate restructuring, market chatter focuses on the stock's potential for substantial upward movement.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions is trending due to a strategic manufacturing partnership with Syrma Johari MedTech, which aims to scale production of its fingerprinting drug screening reader and anticipates substantial cost savings. This positive news, however, is being overshadowed by a significant private placement and share offering that has fueled community concerns over potential dilution. Traders are actively debating the impact of this offering on the stock's recent volatility and future price trajectory.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is actively trending as the community speculates it could be the next low-float SPAC to experience a substantial price surge, drawing parallels to recent strong performers like ESHA. Traders are enthusiastically discussing a potential significant move, driven by the broader "low float SPAC bubble" theme and the perceived ease of high-percentage gains. This collective anticipation is fueling positioning and elevated trading activity.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending as a low-float SPAC, sparking widespread community discussion about its potential for explosive upward movement. Traders are actively debating whether it will follow the recent parabolic runs seen in similar micro-float companies, with many advocating for holding positions amid high volatility. The conversation emphasizes the stock's thin order book and the perceived impact of high insider ownership on its price action.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is generating significant buzz amidst polarized community sentiment, with discussions centering on potential catalysts like substantial ETF inflows and rapidly depleting exchange reserves sparking "supply shock" speculation. However, many remain wary of upcoming token releases and perceived market manipulation, fueling a sharp debate between those anticipating a major price surge and skeptics who highlight past unfulfilled predictions, as the long-term outlook continues to hinge on growing institutional adoption and regulatory clarity.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant momentum after the FDA granted Priority Review for its AXS-05 supplemental New Drug Application targeting agitation in Alzheimer's disease, establishing a clearer regulatory path for this key pipeline candidate. This development, coupled with positive feedback on the AXS-12 narcolepsy program, has ignited widespread enthusiasm among investors who are celebrating a 'Grand Slam Home Run' and anticipating substantial future growth. The community is actively discussing the stock's impressive surge to new highs, with many declaring short sellers 'fuked' and expressing strong conviction in Axsome's long-term potential in CNS therapeutics.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending after announcing $10 million in new autonomous systems orders, a key catalyst driving significant bullish sentiment among investors. The community is buzzing with optimism about the company's strong position in the growing global counter-drone and autonomous defense sectors, anticipating further substantial contract awards and growth in 2026. This positive outlook is further bolstered by the recent launch of a 2x long ETF specifically tracking ONDS.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently a hot topic as investors react to the Federal Reserve's recent rate cut and planned bond purchases, alongside an anticipated Bank of Japan policy decision. The community is sharply split: some expect a significant rally driven by further easing and potential deflation, while others anticipate continued pressure from persistent inflation and large government deficits, questioning the effectiveness of current central bank strategies.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome faced an FDA rejection, providing a clearer path for Xeris's approved treatment, Recorlev. The community is actively discussing why the positive competitive development for Xeris hasn't yet led to a more substantial price movement. Analysts generally view this as a significant tailwind for Recorlev to expand its market share within the growing Cushing's syndrome market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


8xbet2dev

8xbet2dev